文献速递眼底病与葡萄膜炎

比较眼底自发荧光与基于光学相干断层扫描评估Pegcetacoplan治疗地图样萎缩的疗效反应

Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy.
PubMed 文献 · Am J Ophthalmol · 2022-07-16

该研究为2期多中心随机假手术对照试验的事后分析,对113只眼(38只每月注射、36只隔月注射、39只假手术)的OCT容积进行视网膜色素上皮、椭圆体带和外界膜丢失的手动标注。结果显示每月注射组视网膜色素上皮丢失增长中位数显著慢于假手术组,椭圆体带丢失增长也显著慢于假手术组,外界膜丢失增长组间无显著差异;OCT与眼底自发荧光测量地图样萎缩面积具有一致性。

要点

  • 每月注射组视网膜色素上皮丢失增长中位数0.158显著慢于假手术组0.255(P=0.014)。
  • 每月注射组椭圆体带丢失增长中位数0.127显著慢于假手术组0.232(P=0.017)。
  • 外界膜丢失增长在各治疗组间无显著差异(P=0.114)。

核心结论

  • OCT成像在评估地图样萎缩增长方面与眼底自发荧光提供了一致的结果。
  • 除视网膜色素上皮萎缩进展较慢外,OCT还识别出Pegcetacoplan治疗患者椭圆体带损伤的显著减少,提示OCT可能作为地图样萎缩治疗中更敏感监测工具。

研究设计与样本

  • 2期多中心随机假手术对照试验的事后分析。
  • 对FILLY试验基线和第12个月OCT容积进行视网膜色素上皮、椭圆体带和外界膜丢失的手动标注。
  • 纳入113只眼(113例患者:38只每月注射,36只隔月注射,39只假手术),共11,074张B扫描。

主要发现

  • 视网膜色素上皮丢失增长中位数:每月注射组0.158(0.057-0.296)vs 假手术组0.255(0.188-0.359),P=0.014,每月注射组显著更慢。
  • 椭圆体带丢失增长中位数:每月注射组0.127(0.041-0.247)vs 假手术组0.232(0.130-0.349),P=0.017,每月注射组显著更慢。
  • 外界膜丢失增长在各治疗组间无显著差异(P=0.114)。

关键数值与推荐

  • 视网膜色素上皮丢失增长中位数:每月注射组0.158(0.057-0.296)vs 假手术组0.255(0.188-0.359),P=0.014。
  • 椭圆体带丢失增长中位数:每月注射组0.127(0.041-0.247)vs 假手术组0.232(0.130-0.349),P=0.017。
  • 外界膜丢失增长:组间无显著差异,P=0.114。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform an optical coherence tomography (OCT)-based analysis of geographic atrophy (GA) progression in patients treated with pegcetacoplan. DESIGN: Post hoc analysis of a phase 2 multicenter, randomized, sham-controlled trial. METHODS: Manual annotation of retinal pigment epithelium (RPE), ellipsoid zone (EZ), and external limiting membrane (ELM) loss was performed on OCT volumes from baseline and month 12 from the phase 2 FILLY trial of intravitreal pegcetacoplan for the treatment of GA secondary to age-related macular degeneration. MAIN OUTCOME MEASURES: Correlation of GA areas measured on fundus autofluorescence and OCT. Difference in square root transformed growth rates of RPE, EZ, and ELM loss between treatment groups (monthly injection [AM], injection every other month [AEOM], and sham [SM]). RESULTS: OCT volumes from 113 eyes of 113 patients (38 AM, 36 AEOM, and 39 SM) were included, resulting in 11 074 B-scans. The median growth of RPE loss was significantly slower in the AM group (0.158 [0.057-0.296]) than the SM group (0.255 [0.188-0.359], P = .014). Importantly, the growth of EZ loss was also significantly slower in the AM group (0.127 [0.041-0.247]) than the SM group (0.232 [0.130-0.349], P = .017). There was no significant difference in the growth of ELM loss between the treatment groups (P = .114). CONCLUSIONS: OCT imaging provided consistent results for GA growth compared with fundus autofluorescence. In addition to slower RPE atrophy progression in patients treated with pegcetacoplan, a significant reduction in EZ impairment was also identified by OCT, suggesting the use of OCT as a potentially more sensitive monitoring tool in GA therapy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mai J, Riedl S, Reiter GS, et al. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy. Am J Ophthalmol. 2022. PMID: 35853489. doi:10.1016/j.ajo.2022.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。